Lincoln Pharmaceuticals (531633) Q3 24/25 earnings summary

Executive summary

• Standalone net profit for Q3 FY25 was Rs. 20.77 crore, down 25.93% year-over-year; revenue from operations was Rs. 146.55 crore, nearly flat compared to Q3 FY24.

• For 9M FY25, net profit was Rs. 70.77 crore, down 5.27% year-over-year; revenue from operations grew 3.88% to Rs. 455.05 crore.

• EBITDA for Q3 FY25 was Rs. 32.63 crore, a 19.79% decline year-over-year; for 9M FY25, EBITDA was Rs. 104.13 crore, down 4.41%.

• Company targets Rs. 750 crore revenue by FY26, driven by expansion into high-value product lines and new markets.

• FII holding increased to 5.16% as of Dec 2024 from 3.22% in Dec 2023.

Financial highlights

• Q3 FY25 revenue from operations: Rs. 146.55 crore (up 0.07% year-over-year).

• Q3 FY25 net profit: Rs. 20.77 crore (down 25.93% year-over-year).

• 9M FY25 revenue from operations: Rs. 455.05 crore (up 3.88% year-over-year).

• 9M FY25 net profit: Rs. 70.77 crore (down 5.27% year-over-year).

• 9M FY25 EBITDA: Rs. 104.13 crore (down 4.41% year-over-year).

Outlook and guidance

• Company aims to achieve Rs. 750 crore revenue by FY26, focusing on business expansion and new product launches.

• Strategic initiatives include entry into new geographies and high-value product lines.

• Maintains net debt-free status and strong liquidity, supported by healthy cash accruals.